

News Release

April 15, 2022
Carna Biosciences, Inc.

Gilead presented a novel DGK α inhibitor Licensed from Carna

Gilead presented an investigational novel DGK α inhibitor discovered from the immune-oncology program licensed from Carna at the company's "Oncology Deep Dive" held on April 14 (EDT).

In June 2019, Carna licensed Gilead worldwide rights to develop and commercialize small molecule compounds in immuno-oncology, targeting DGK α .

"We are very pleased that our collaboration program was introduced as one of the highlighted examples among many of Gilead's collaborations. We highly appreciate the tremendous effort from the Gilead team in identifying a novel DGK α inhibitor GS-9911 from our collaboration. We continue our research and development with utmost effort to deliver an innovative therapy for patients suffering from diseases," said Kohichiro Yoshino, Ph.D., President and Chief Executive Officer at Carna Biosciences.

Under the terms of the license agreement, Carna received an upfront payment of \$20 million in June 2019 and is eligible to receive up to an additional \$450 million in potential milestone payments upon achievement of certain development and commercial milestones, including the first milestone payment received in December 2021. Carna will also receive royalties on future net sales.

Please refer to Gilead's website for the details of the presentation.

URL: <https://investors.gilead.com/events>

Contact:

Corporate Planning

Carna Biosciences, Inc.

TEL: +81-78-302-7075

<https://www.carnabio.com/english/>